Company Overview
Damora Therapeutics, Inc. operates as a clinical-stage biotechnology entity focused on developing molecule therapeutics designed to treat conditions such as fibrosis, cancer, inflammation, and other related diseases. The company's strategic pipeline includes the development of GB3226, a preclinical small molecule dual inhibitor targeting ENL-YEATS and FLT3, alongside GB1211, an oral small molecule. This organization functions within the broader Healthcare sector and specifically the Biotechnology industry, environments characterized by high research and development expenditures and regulatory scrutiny before product commercialization. With a market capitalization of $1.73B, Damora Therapeutics holds a valuation that significantly exceeds its current operational scale, as reflected by its reported annual revenue of N/A and an employee count of 5. The disparity between the substantial market cap and the lack of reported revenue indicates that the company's value is derived primarily from its intellectual property portfolio and preclinical stage assets rather than current cash-generating operations.
Financial Health
The company reports a Net Income (TTM) of $-15,844,000 and an EBITDA of $-11,862,000, while its Revenue (TTM) is listed as N/A. The absence of reported revenue alongside significant negative net income reveals a cost structure dominated by research and development expenses and general administrative costs typical of a pre-revenue biotechnology firm. Free Cash Flow stands at $-7,066,875, indicating that the company is currently burning cash to fund its scientific pipeline and operational activities rather than generating liquidity from sales. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, a figure that reflects the inability to calculate traditional profitability ratios in the absence of revenue data and underscores the non-income-generating nature of the business at this stage. The balance sheet shows Cash holdings of $7.61M against total Debt of $72,000, creating a scenario where liquid assets vastly exceed liabilities. This disparity supports a Debt to Equity ratio of 0.90, suggesting that while the company carries debt relative to equity, its financial position is not leveraged in a manner that threatens solvency given the minimal debt load. The Current Ratio is 3.73, which indicates a strong short-term liquidity position where current assets are more than three times current liabilities, providing ample buffer for meeting immediate obligations. Furthermore, the Return on Equity is -109.5% and the Return on Assets is -43.5%, metrics that reveal management is currently utilizing shareholder capital and assets to generate losses rather than returns, a common characteristic of clinical-stage biotechs prior to successful product approvals.
Valuation Assessment
The trailing P/E Ratio (TTM) is N/A due to the lack of positive earnings, while the Forward P/E is -30.20, implying that the market is pricing in future profitability that has not yet been realized. The Price to Book ratio stands at 5.71, indicating that the market values the company at a significant premium over its book value, likely driven by the perceived potential of its preclinical assets and pipeline. The Price to Sales ratio is N/A, and the EV/EBITDA is -2.33, suggesting that traditional valuation multiples based on revenue or earnings are not applicable and that the valuation relies heavily on asset quality and future commercial potential. The stock has a 52-Week High of $38.33 and a 52-Week Low of $2.01, placing the current trading price in a highly volatile range relative to its historical extremes. With a Beta of 1.57, the stock exhibits price volatility that is substantially higher than the broader market, meaning it is expected to fluctuate with greater intensity during periods of market stress or growth. These valuation metrics collectively paint a picture of a high-risk, high-reward asset where current pricing does not correlate with traditional financial performance indicators.
Growth & Income
The Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A, as the company has not yet generated commercial revenue to support year-over-year growth calculations. Consequently, earnings are not growing faster or slower than revenue in a traditional sense, as both metrics are currently undefined by historical performance data. As a non-dividend payer with a Dividend Yield of N/A and a Payout Ratio of 0.0%, the company does not distribute income to shareholders but instead retains all cash flow to reinvest into research, development, and clinical trial expansion. The overall growth and income profile is defined entirely by the company's ability to advance its clinical pipeline rather than by historical financial growth rates or dividend distributions to investors.